Protein expression of MED12 and ER in tumours with wild-type MED12 and mutant MED12
| MED12 wild-type | MED12 mutants | Type of mutation | ||||
|---|---|---|---|---|---|---|
| Missense | Indels | Splice site | p Value | |||
| MED12 protein expression in stroma (N=212) | ||||||
| Low (H-score ≤150) | 12 (15.4) | 8 (6) | 3 (2.9) | 4 (15.4) | 1 (20) | 0.029* |
| High (H-score >150) | 66 (84.6) | 126 (94) | 100 (97.1) | 22 (84.6) | 4 (80) | 0.023† |
| MED12 protein expression in epithelium (N=211‡) | ||||||
| Low (H-score ≤150) | 4 (5.1) | 5 (3.8) | 2 (1.9) | 2 (8.0) | 1 (20) | 0.729* |
| High (H-score >150) | 74 (94.9) | 128 (96.2) | 101 (98.1) | 23 (92.0) | 4 (80) | 0.054† |
| ERα in epithelium (N=168) | ||||||
| Negative | 2 (3.1) | 9 (8.7) | 7 (8.3) | 2 (11.1) | 0 (0) | 0.209* |
| Positive§ | 62 (96.9) | 95 (91.3) | 77 (91.7) | 16 (88.9) | 2 (100) | 0.845† |
| ERβ in epithelial nucleus (N=168) | ||||||
| Negative | 11 (17.2) | 12 (11.5) | 11 (13.1) | 1 (5.6) | 0 (0) | 0.357* |
| Positive§ | 53 (82.8) | 92 (88.5) | 73 (86.9) | 17 (94.4) | 2 (100) | 0.579† |
| ERβ in epithelial cytoplasm (N=168) | ||||||
| Negative | 27 (42.2) | 39 (37.5) | 32 (38.1) | 6 (33.3) | 1 (50) | 0.626* |
| Positive§ | 37 (57.8) | 65 (62.5) | 52 (61.9) | 12 (66.7) | 1 (50) | 0.870† |
| ERβ in stromal nucleus (N=168) | ||||||
| Negative | 41 (64.1) | 62 (59.6) | 50 (59.5) | 10 (55.6) | 2 (100) | 0.626* |
| Positive§ | 23 (35.9) | 42 (40.4) | 34 (40.5) | 8 (44.4) | 0 (0) | 0.478† |
| ERβ in stromal cytoplasm (N=168) | ||||||
| Negative | 53 (82.8) | 85 (81.7) | 72 (85.7) | 11 (61.1) | 2 (100) | 1.000* |
| Positive§ | 11 (17.2) | 19 (18.3) | 12 (14.3) | 7 (38.9) | 0 (0) | 0.039† |
*MED12 wild-type versus MED12 mutants.
†Missense versus indels versus splice site mutations.
‡One malignant tumour was without an epithelial component.
§Positivity was defined by at least 1% immunoreactive tumour nuclei.
ER, oestrogen receptor.